{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T16:08:39Z","timestamp":1772986119280,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.pathol.2023.10.006","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T22:11:12Z","timestamp":1700777472000},"page":"391-397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The first human normative ranges and biomarker performance of dimethylguanidino valeric acid isoforms in fatty liver disease"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-9324","authenticated-orcid":false,"given":"Sami","family":"Qadri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XiaoSuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Collin","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5797-6854","authenticated-orcid":false,"given":"Michael","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Bonnitcha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannele","family":"Yki-J\u00e4rvinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2023.10.006_bib1","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1172\/JCI95995","article-title":"Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes","volume":"127","author":"O\u2019Sullivan","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pathol.2023.10.006_bib2","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","article-title":"Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population","volume":"288","author":"Szczepaniak","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.pathol.2023.10.006_bib3","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pathol.2023.10.006_bib4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.pathol.2022.01.008","article-title":"Design and validation of an LC-MS\/MS method for simultaneous quantification of asymmetric dimethylguanidino valeric acid, asymmetric dimethylarginine and symmetric dimethylarginine in human plasma","volume":"54","author":"Bonnitcha","year":"2022","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2023.10.006_bib5","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162513","article-title":"Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease","volume":"132","author":"Tamaki","year":"2022","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pathol.2023.10.006_bib6","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.3390\/ijms20184592","article-title":"The second life of methylarginines as cardiovascular targets","volume":"20","author":"Jarzebska","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pathol.2023.10.006_bib7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jhep.2021.04.011","article-title":"Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease","volume":"75","author":"Yoo","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pathol.2023.10.006_bib8","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/cvr\/cvaa051","article-title":"Effect of chronic exercise in healthy young male adults: a metabolomic analysis","volume":"117","author":"Koay","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pathol.2023.10.006_bib9","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1001\/jamacardio.2019.1573","article-title":"Association of dimethylguanidino valeric acid with partial resistance to metabolic\u00a0health\u00a0benefits of regular exercise","volume":"4","author":"Robbins","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.pathol.2023.10.006_bib10","article-title":"Dimethylguanidino valerate: a lifestyle-related metabolite associated with future coronary artery disease\u00a0and cardiovascular mortality","volume":"8","author":"Ottosson","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.pathol.2023.10.006_bib11","doi-asserted-by":"crossref","first-page":"E509","DOI":"10.1152\/ajpendo.00207.2020","article-title":"Nutritional and metabolic regulation of the metabolite dimethylguanidino valeric acid: an early marker of cardiometabolic disease","volume":"319","author":"Wali","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302523002969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302523002969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T22:09:02Z","timestamp":1710454142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302523002969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0031302523002969"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2023.10.006","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The first human normative ranges and biomarker performance of dimethylguanidino valeric acid isoforms in fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2023.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia.","name":"copyright","label":"Copyright"}]}}